South Korea Cancer Diagnostics Market Insights, 2031

Key Insights

• According to the research report, "South Korea Cancer Diagnostics Market Outlook, 2031," published by Bonafide Research, the South Korea Cancer Diagnostics Market is expected to reach a market size of more than 1.36 Billion by 2031.
• South Korea’s cancer diagnostics landscape is characterized by the widespread integration of Next-Generation Sequencing (NGS) and molecular liquid biopsy assays into routine clinical workflows, supported by universal coverage under the National Health Insurance (NHI) system. A major technological breakthrough includes the domestic commercialization of highly sensitive circulating tumor DNA (ctDNA) assays and multi-gene NGS panel tests tailored specifically to Asian genetic profiles for lung, gastric, and colorectal cancers. Major university hospitals and tertiary medical centers leverage these molecular assays to guide targeted therapies and monitor minimal residual disease (MRD) without necessitating invasive tissue resections, solidifying South Korea’s status as a regional precision oncology hub.
• To handle severe patient volumes across metropolitan hospital hubs, South Korean diagnostic laboratories and medical imaging departments are rapidly adopting artificial intelligence (AI) software. Leading domestic medical AI pioneers have achieved major technical milestones by integrating deep-learning algorithms into low-dose CT scans, digital mammography, and high-resolution endoscopic systems to detect early-stage micro-lesions in lung, breast, and stomach cancers. Concurrently, digital pathology networks across major hospitals utilize AI image-analysis algorithms to automate biomarker scoring (e.g., HER2, PD-L1, Ki-67), accelerating diagnostic turnaround times and standardizing clinical precision. Over 270,000 new cancer cases are diagnosed annually across South Korea, driven by an aging demographic structure and structured public screening initiatives.

Market Outlook

• Government policies continue to expand subsidized access through the National Cancer Screening Program (NCSP) for high-incidence malignancies, while integrating novel non-invasive modalities such as liquid-based cytology and HPV-DNA testing. Important national associations, clinical research hubs, and regulatory bodies setting standards and driving technology adoption include the Korean Cancer Association (KCA), the Korean Society of Medical Oncology (KSMO), the Korean Society of Pathologists (KSP), the National Cancer Center Korea (NCC), and the Ministry of Food and Drug Safety (MFDS). Major commercial players driving diagnostic hardware, molecular assay development, and testing service distribution across South Korea include Seegene, SD Biosensor, Lunit, JLK, Gencurix, Macrogen, Roche Diagnostics, Siemens Healthineers, Thermo Fisher Scientific, Illumina, and Abbott Laboratories.
•

Market Dynamics

Driver: Universal NHI coverage for molecular biomarkers and strategic precision medicine mandates
The primary growth driver for South Korea's cancer diagnostics market is the universal, centralized coverage provided by the National Health Insurance (NHI) system, combined with federal precision medicine policies under the Ministry of Health and Welfare (MOHW). Facing a rapidly aging demographic where chronic disease burden is escalating, the South Korean government prioritizes early detection and targeted interventions to manage long-term oncology expenditures. The NHI universally reimburses comprehensive multi-gene Next-Generation Sequencing (NGS) panels, fluorescent in situ hybridization (FISH) tests, and companion diagnostics (CDx) when conducted in accredited tertiary medical centers.
Challenge: over-concentration in metropolitan medical hubs and severe domestic price compression
The most significant headwind confronting the South Korean cancer diagnostics sector is the heavy geographic centralization of diagnostic workloads in the Seoul Capital Area (SCA), compounded by aggressive fee reductions enforced by the Health Insurance Review and Assessment Service (HIRA). Major tertiary hospitals in Seoul (the "Big 5" medical centers) handle more than 70% of complex diagnostic testing, creating severe operational bottlenecks, long patient waiting lists, and resource underutilization in provincial regional hospitals.
Trend: Hyper-adoption of AI-driven imaging, automated pathology, and domestic software innovations
A defining structural trend reshaping South Korea's cancer diagnostic landscape is the rapid integration of artificial intelligence (AI) across diagnostic imaging, digital histopathology, and multi-omics analysis. Supported by fast-track regulatory evaluation programs under the Ministry of Food and Drug Safety (MFDS), South Korea has emerged as a global testing ground for clinical AI. Leading domestic medical AI pioneers (such as Lunit and JLK) deploy deep-learning algorithms into low-dose CT scans, digital mammography, and high-resolution GI endoscopy to detect micro-lesions and pre-cancerous nodules with high accuracy.

Segment Analysis

South Korea Cancer Diagnostics By Product Type
• South Korea’s cancer diagnostics consumables and reagents segment serves hospital laboratories, specialized pathology centers, molecular diagnostic providers, and biotechnology companies. Products include immunohistochemistry antibodies, PCR reagents, nucleic acid extraction kits, sequencing consumables, tissue-staining materials, and assays for detecting tumor-associated genetic alterations. A distinctive market feature is the combination of advanced clinical testing requirements with a strong domestic biotechnology industry that develops molecular diagnostic products and specialized assays.
• South Korea’s cancer diagnostics instruments segment includes molecular analyzers, PCR systems, sequencing platforms, automated tissue processors, immunostaining equipment, digital pathology systems, and advanced imaging technologies. The market benefits from technologically sophisticated hospitals, established electronics and medical device capabilities, and domestic companies developing diagnostic platforms. A distinctive characteristic is the opportunity to integrate diagnostic equipment with automated laboratory workflows and hospital information systems, supporting efficient testing and reporting.



South Korea Cancer Diagnostics By Technology
• In vitro diagnostic testing in South Korea encompasses PCR-based assays, next-generation sequencing, immunoassays, immunohistochemistry, and other molecular techniques used to detect cancer-associated biomarkers. A distinctive feature is the combination of domestic molecular diagnostic innovation with sophisticated hospital-based oncology services. South Korean companies have developed specialized assays for mutation detection and cancer-related biomarker analysis, supporting the country's broader precision medicine ecosystem.
• Anatomic pathology in South Korea includes histopathology, cytology, immunohistochemistry, tissue processing, and molecular pathology. Its distinctive market characteristic is the integration of conventional tissue examination with advanced biomarker testing in specialist hospitals and diagnostic laboratories. Pathologists increasingly need to combine morphological findings with molecular information to classify tumors and support personalized treatment decisions. This creates demand for automated staining systems, tissue processors, specialized antibodies, and digital pathology solutions.
• Diagnostic imaging in South Korea includes mammography, ultrasound, computed tomography, magnetic resonance imaging, and positron emission tomography used for cancer screening, diagnosis, staging, and follow-up. A distinctive characteristic is the role of the National Cancer Screening Program, which incorporates screening pathways for several common cancers, including stomach, colorectal, breast, cervical, liver, and lung cancers. This creates demand for imaging technologies that fit established screening and diagnostic workflows.
• Biopsy technologies in South Korea include core-needle sampling, fine-needle aspiration, endoscopic biopsy, image-guided tissue collection, and surgical biopsy procedures. The segment is distinguished by the importance of obtaining sufficient material for both conventional pathological examination and molecular profiling. Endoscopic biopsy is particularly relevant within established gastric and colorectal diagnostic pathways, while image-guided sampling supports investigations of suspicious lesions identified through radiological assessment. Liquid biopsy is an additional area of interest, with domestic biotechnology companies developing approaches to analyze circulating tumor DNA and other cancer-associated biomarkers.

South Korea Cancer Diagnostics By Application
• South Korea's breast cancer diagnostics segment is closely connected to national screening pathways, mammography, diagnostic ultrasound, biopsy, and pathological biomarker testing. A distinctive feature is the established role of mammography within the National Cancer Screening Program, alongside specialist hospital services for evaluating suspicious findings. Ultrasound and additional imaging can help characterize lesions, while biopsy and histopathology establish the diagnosis. Immunohistochemistry for hormone receptors and HER2 is important for determining tumor characteristics and guiding treatment selection.
• Colorectal cancer diagnostics in South Korea combine organized screening, fecal occult blood testing, colonoscopy, biopsy, histopathology, and molecular testing. A distinctive characteristic is the connection between the National Cancer Screening Program and follow-up diagnostic procedures: suspicious screening results require appropriate endoscopic evaluation and, where indicated, tissue confirmation. Molecular testing can subsequently help characterize tumors and guide treatment decisions, including assessment of mismatch repair status and relevant genetic alterations. This creates demand for screening reagents, endoscopic equipment, tissue-processing materials, immunohistochemistry, and molecular assays.
• South Korea's lung cancer diagnostics segment combines low-dose computed tomography screening for eligible high-risk individuals, diagnostic imaging, biopsy, histopathology, and molecular testing. A distinctive market feature is the integration of lung cancer screening into the National Cancer Screening Program, creating a pathway from identifying suspicious pulmonary lesions to confirmatory investigations. Biopsy and pathological assessment establish tumor type, while molecular testing can identify treatment-relevant alterations such as EGFR and other actionable biomarkers where clinically indicated. These needs support demand for advanced imaging equipment, bronchoscopy and biopsy devices, immunohistochemistry reagents, and molecular diagnostic platforms.
• South Korea's prostate cancer diagnostics segment includes prostate-specific antigen testing, clinical evaluation, imaging, prostate biopsy, histopathology, and selected molecular or genetic investigations. Its distinctive characteristic is the need to balance early detection with careful assessment of whether a suspected tumor is clinically significant. MRI can help identify suspicious lesions and inform biopsy planning, while pathological grading supports risk classification and treatment decisions. Unlike cancers covered by South Korea's principal national screening pathways, prostate cancer diagnostics rely more heavily on individual clinical assessment and the decisions of patients and healthcare professionals.
• The other applications segment includes stomach, liver, cervical, ovarian, pancreatic, kidney, skin, hematological, and other malignancies. A distinctive feature of South Korea's cancer diagnostics landscape is the inclusion of several of these cancers in established national screening pathways, particularly stomach and liver cancers, alongside colorectal, breast, cervical, and lung cancers. Screening and diagnostic methods vary by disease: gastric cancer assessment frequently involves endoscopy and biopsy, liver cancer surveillance may combine ultrasound with laboratory testing in eligible high-risk groups, and cervical cancer assessment can involve cytology and HPV-related testing.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Cancer Diagnostics Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Consumables and reagents
• Instruments

By Technology
• IVD testing
• Anatomic pathology
• Diagnostic imaging
• Biopsy

By Application
• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Prostate Cancer
• Others